What we're reading, December 22, 2016: Americans continue to sign up for Obamacare coverage despite Republicans' promise to repeal the law; California is implementing a $3 billion effort to help the state’s neediest individuals; and Zika vaccine shows success.
As Republicans are poised to repeal the Affordable Care Act (ACA), Americans are continuing to sign up in record numbers. The New York Times reported that there has already been a 400,000 increase in new sign-ups over the same time last year, plus hundreds of thousands of people are being auto-enrolled into the same or similar plans as last year. Interestingly, the 5 states with the most sign-ups all voted for President-elect Donald Trump, who has promised to make an ACA repeal one of his first acts.
California is implementing a $3 billion effort to help the state’s neediest individuals. Projects include connecting former inmates with health clinics and social services, getting homeless people in housing, and providing a place for homeless patients to stay after they leave the hospital, reported Kaiser Health News. The aim of the effort is to combine physical care, mental health care, and social services for the most complex and costly patients in California.
In an early-stage study, an experimental Zika vaccine evoked robust responses in human volunteers. According to Reuters, the study’s volunteers had Zika-specific immune responses after treatment with no significant safety concerns after 14 weeks. There are still no approved vaccines or treatments for the virus, which has spread to more than 60 countries and territories.
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More